reports
- Eric Yoo
- Eric Yoo
- Alex Cogut
- Eric Yoo
VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release i...
VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release is a clearing event for IPF update in Q4 • -> COVID19 Phase 3 ATTRACT trial is a clearing event • -> We maintain a BUY rating with SEK60 TP, COVID was not in our model
- Eric Yoo
VICORE PHARMA BUY – SEK60 Up and AT2'em: initiating coverage on a prom...
VICORE PHARMA – initiating with a BUY Vicore Pharma is developing an angiotensin II type 2 receptor (ATR2) agonist (C21/VP01) for IPF and PAH. We are encouraged by C21’s durable disease-modifying potential in IPF shown in a first interim analysis of the ongoing phase 2 AIR trial. In 7 evaluable patients, FVC improved by +750 mL at week 36, which no other candidate has demonstrated to date. We expect an additional interim update and plans for C21’s further development in Q4 2022. We believe there...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.